2009다75178
2009Da75178 Decided July 28, 2011 [Compensation for Employee Invention]
[Main Issues and Holdings]
[1] Criteria to determine whether a person is considered to be a joint inventor
[2] In a case where Gap worked at Eul corporation as Project Leader in charge of product development for Pyribenzoxim and other herbicides, contributed to full-scale commercialization of Pyribenzoxim by directly involving himself in various experiments and, upon learning that commercialization of another herbicide candidates manufactured by Byung's research team in the Korea Research Institute of Chemical Technology had been suspended at the product development stage due to its high level of toxicity, proposed joint research to solve this toxicity issue, eventually allowing Eul corporation to complete its patented invention for a herbicidal emulsion composite and patented invention for a herbicidal pyridine sulphonylurea, the Court affirmed the judgment of the court below to acknowledge Gap as joint inventor for the above inventions
[3] The extinctive period for a compensation claim to an employee invention (=10 years) and the point that the period begins to run
[4] The meaning of "profit realized by the employer," as stipulated in Article 40 (2) of the former Patent Act to consider when assessing compensation amounts for an employee invention
[Summary of Decision]
[1] A joint inventor must be established as being in a relationship of mutual cooperation, on an actual basis, toward completion of the invention. Accordingly, the status of a joint inventor is acknowledged when a person has contributed toward completion of the invention by more than merely providing basic tasks or ideas for the invention, providing general administration for researchers, organizing data and performing experiments upon instruction by a researcher, or supporting or commissioning completion of the invention by providing funds or equipment. Rather, a joint inventor must have contributed toward the invention by newly presenting or adding/supplementing concrete conceptions in regard to technical problems within the invention, materializing new conceptions by conducting experiments, etc., or providing concrete means and methods to achieve the purpose and utility of the invention or by providing actual advice and/or instructions that make the invention possible.
In other words, a person must have contributed toward creational activity of the technical idea to an actual extent in order to be recognized as a joint inventor. Meanwhile, in the case of chemical inventions, which take place in a field frequently referred to as "the science of experiments," notwithstanding certain disparities that may be caused by the contents and technical level of an invention in this field, there are many cases where the invention substantially lacks predictability or implementability and thus cannot be seen as a complete invention without a trial experiment to present experiment data. In such cases, the status of a joint inventor must be decided considering whether the person in question made actual contributions toward specifically defining and completing the invention in the process of experiment.
[2] In a case where Gap worked at Eul corporation as Project Leader (PL) in charge of product development for Pyribenzoxim, a herbicide invented by modifying bispyribac and used for direct-seeded rice, and other herbicides, contributed to full-scale commercialization of Pyribenzoxim by directly involving himself in various experiments for registration testing, toxicity testing, mass production procedures and residue testing, etc., and, upon learning that commercialization of another herbicide candidates manufactured by a research team led by Byung at the Korea Research Institute of Chemical Technology had been suspended at the product development stage due to its high level of toxicity, proposed joint research to solve this toxicity issue, eventually allowing Eul corporation to complete its patented invention for a herbicidal emulsion composite and a patented invention for a herbicidal pyridine sulphonylurea (generic name "Flucetosulfuron"), the Court affirms the judgment of the court below which acknowledged Gap as joint inventor for the above inventions, on the grounds that Gap had made the invention possible by providing concrete conceptions in his capacity as PL, enabling subordinates to proceed with and realize advances during the process of the patented invention, and by providing specific guidance when research remained in a state of confusion.
[3] A compensation claim for an invention made in connection with employment (an "employee invention") is barred because of the extinctive prescription if not exercised for ten years, just as with general claims. Generally speaking, the starting point of running of an extinctive prescription period is when the employer succeeds from the employee the right to obtain a patent for the invention. However, in cases where a company has internal regulations defining a time period to pay compensation for employee inventions, this prescribed time of payment becomes the starting point of running of the extinctive prescription period, out of consideration that an employee has a legal barrier from exercising his/her right to claim compensation before this time has come.
[4] Article 40 (2) of the former Patent Act (amended by Act No. 6411 of Feb. 3, 2001) states that, in cases where the employer succeeds to the right to obtain a patent or the patent right for an employee invention, the amount of compensation to be paid to the employee should be determined upon consideration of the amount of profits which the employer makes on the invention and the degree of contribution made by the employer for completion of the invention. Article 39 (1) of the same Act states that, even when the employer has not succeeded to a patentable right for such an employee invention, the employer shall have an ordinary right of use of the invention. Therefore, in this context the amount of profit made by the employer signifies more than profit realized through an ordinary right of use and indicates the amount of profit acquired through the right to exclusive and monopolistic use.
Meanwhile, the amount of profits made by the employer in this context signifies profit gained due to the employee invention itself, not the accounting profit left after balancing profit with cost. As so, if there is profit arising from the employee invention itself there is profit made by the employer, and even when the product manufactured and sold by the employer does not fall under the scope of right for the employee invention, if this product is a substitute that carries the employee invention and the patent right on the employee invention prevents competing companies from using such invention, thus increasing sales for the product, this profit can be assessed as the user's profit made from the employee invention.
[Reference Provisions] [1] Article 33 (2) of the former Patent Act (amended by Act No. 6411 of Feb. 3, 2001) / [2] Article 33 (2), Article 39 of the former Patent Act (amended by Act No. 6411 of Feb. 3, 2001) (see Article 10 of the current Invention Promotion Act) / [3] Article 39, Article 40 of the former Patent Act (amended by Act No. 6411 of Feb. 3, 2001) (see Article 10, Article 15 of the current Invention Promotion Act), Article 162, Article 166 (1) of the Civil Act / [4] Article 39 (1), Article 40 (1) (2) of the former Patent Act (amended by Act No. 6411 of Feb. 3, 2001) (see Article 10, Article 15 (1), (3) of the current Invention Promotion Act)
Article 33 of the former Patent Act (Person Entitled to Obtain Patent) (2) If two or more persons make jointly an invention, they shall have jointly the patentable right.
Article 39 of the former Patent Act (Employee's Invention) (1) If an invention made by an employee, officer of a corporation or public official (hereinafter referred to as an "employee, etc.") in connection with his duties belongs by its nature to the scope of activities of the employer, corporation, State or local government (hereinafter referred to as an "employer, etc."), and if the employee, etc. or a person who has succeeded to a patentable right, obtains a patent for an invention the inventive act of which belongs to the present or past duties of the employee, etc. (hereinafter referred to as an "employee's invention"), the employer, etc. shall have an ordinary license on such patent right.
(2) Any employee's invention made by a public official shall be succeeded to the State, and the patent right to such employee's invention of a public official, to which the State succeeds, shall be owned by the State.
(3) Except employee's inventions of those made by employee, etc., any clause of a contract or service rules which allows employer, etc. to succeed, in advance, to a right to obtain a patent or a patent right, or which establishes an exclusive license in favor of employer, etc., shall become null and void.
(4) Notwithstanding the provisions of State Properties ActArticle 6 of the State Properties Act, the disposal and management of any patent right owned by the State under paragraph (2) shall be controlled by the Commissioner of the Korean Industrial Property Office.
(5) Matters necessary for the disposal and management of the State-owned patent rights as referred to in paragraph (4) shall be stipulated by the Presidential Decree.
Article 40 of the former Patent Act (Compensation for Employee's Invention) (1) In the event that employee, etc. have employer, etc. succeed to the right to obtain a patent or the patent right for an employee's invention by a contract or service rules, or establish an exclusive license, they shall be entitled to obtain due compensation.
(2) In determining the amount of compensation as referred to in paragraph (1), the amount of profits which the employer, etc. make on the invention and the degree of contribution made by the employer, etc. for a completion of the invention shall be taken into consideration, and if the employee, etc. present a reasonable method of determination, it shall be taken into consideration.
(3) If the State has succeeded to an employee's invention of a public official under Article 39 (2), the State shall pay a due compensation. In this case, matters necessary for payment of the compensation shall be stipulated by the Presidential Decree.
(4) Deleted.
Article 10 of the Invention Promotion Act (Employee Invention) (1) If an employee acquires a patent or completes the registration of a utility model or design (hereinafter referred to as "patent, etc."), or succeeds to the right to acquire a patent, etc., with regard to an employee invention, the employer shall have a non-exclusive license for the patent, utility model right, or design right (hereinafter referred to as "patent right, etc.").
(2) Notwithstanding paragraph (1), the State or a local government shall succeed to a public official's right to an employee invention, and thus a public official's patent right, etc. for an employee invention, to which the State or a local government succeeds, shall be State property or public property: Provided, That an exclusively responsible organization under the latter part of Article 11 (1) of the Technology Transfer and Commercialization Promotion Act (hereinafter referred to as "exclusively responsible organization") shall succeed to rights of a teaching staff, who works at a national or public school under Article 3 of the Higher Education Act (hereinafter referred to as "national or public school"), to an employee invention, and thus patent rights, etc. of a teaching staff of a national or public school to an employee invention, to which the exclusively responsible organization succeeds, shall be owned by the exclusively responsible organization.
(3) A clause of a contract or employment regulations shall be void, if the clause requires an employee to transfer the right to acquire a patent, etc., or a patent right, etc., to the employer in advance in connection with any invention made by the employee, other than employee inventions, or requires an employee to grant the exclusive license for a patent, etc. to the employer.
(4) Notwithstanding Article 8 of the State Property Act, the disposal and management (including waiver of patent rights, etc.) of patent rights, etc. that become State property pursuant to paragraph (2) shall be under the jurisdiction of the Commissioner of the Korean Intellectual Property Office, and matters necessary for the disposal and management thereof shall be prescribed by Presidential Decree.
Article 15 of the Invention Promotion Act (Compensation for Employee Invention) (1) An employee shall have a right to obtain fair compensation when he/she agrees with his/her employer under a contract or employment regulations to have the employer succeed to his/her rights to the patent, etc. for an employee invention or to grant an exclusive license for an employee invention.
(2) In cases where a contract or employment regulations provide for compensation under paragraph (1), the compensation shall be deemed fair, if it is considered reasonable in light of the following conditions:
1. How negotiations were made between the employer and employees when guidelines for determining the form and amount of compensation were established;
2. How the guidelines were presented to employees, such as whether the guidelines established for compensation were publicly announced or posted;
3. How employees' opinions were heard when determining the form and amount of compensation.
(3) If a contract or employment regulations do not provide for compensation under paragraph (1) or if a compensation cannot be considered as fair compensation under paragraph (2), the amount of such compensation shall be determined by taking into consideration benefits the employer is anticipated to obtain with the invention and the degree of contribution of the employer and the employee to the completion of the invention.
(4) The State or a local government shall pay fair compensation, when it succeeds to rights to an employee invention made by a public official pursuant to Article 10 (2). In such cases, matters necessary for the payment of compensation shall be prescribed by Presidential Decree or Municipal Ordinance.
Article 162 of the Civil Act (Extinctive Prescription of Claims or Property Right) (1) The extinctive prescription of a claim shall become complete if not exercised for a period of ten years.
(2) The extinctive prescription of property rights, other than a claim and ownership, shall become complete if not exercised for a period of twenty years.
Article 166 of the Civil Act (Starting Point of Computing Extinctive Prescription) (1) Extinctive prescription shall run from the time it becomes possible to exercise a certain right.
[Reference Cases] [1] Supreme Court Decision 99Hu468 decided Nov. 27, 2001, Supreme Court Decision 2001Hu65 decided Nov. 30, 2001 (Gong2002Sang, 216)
[Plaintiff-Appellee-Appellant] Plaintiff (Law Firm Apex, Attorneys Park Gyun-je et al., Counsel for plaintiff-appellee-appellant)
[Defendant-Appellant-Appellee] LG Life Sciences Ltd. (Law Firm Lee & Ko, Attorneys Lee Gyu-hong et al., Counsel for defendant-appellant-appellee)
[Judgment of the court below] Seoul High Court Decision 2008Na119134 decided Aug. 20, 2009
[Disposition] All appeals are dismissed. Costs of appeals are assessed to each parties.
[Reasoning] The grounds for appeal are examined as follows.
1. The defendant's first and second grounds for appeal
A. A joint inventor must be established as being in a relationship of mutual cooperation, on an actual basis, toward completion of the invention (see Supreme Court Decision 99Hu468, Nov. 27, 2001). Accordingly, the status of a joint inventor can be acknowledged when a person has contributed toward completion of the invention by more than merely providing basic tasks or ideas for the invention, providing general administration for researchers, organizing data and performing experiments upon instruction by a researcher, or supporting or commissioning completion of the invention by providing funds or equipment. Rather, a joint inventor must have contributed toward the invention by newly presenting or adding/supplementing concrete conceptions in regard to technical problems within the invention, materializing such new conceptions by conducting experiments, etc., or providing concrete means and methods to achieve the purpose and effect of the invention or by providing concrete advice or instructions that make the invention possible. In other words, a person must have contributed toward creational activity of the technical idea to an actual extent in order to be recognized as a joint inventor. Meanwhile, in the case of chemical inventions, which take place in a field frequently referred to as "the science of experiments," notwithstanding certain disparities that may be caused by the contents and technical level of an invention in this field, there are many cases where the invention substantially lacks predictability or implementability and thus cannot be seen as a complete invention without a trial experiment to present experiment data. (see Supreme Court Decision 2001Hu65, Nov. 30, 2001). In such cases, the status of a joint inventor must be decided considering whether the person in question made actual contributions toward specifically defining and completing the invention in the process of experiment.
B. According to the reasoning of its judgment, the following facts were established at the court below. (1) Researchers at the defendant company invented the substance Pyribenzoxim in 1991 by modifying bispyribac, a herbicide used for direct-seeded rice. In lab tests Pyribenzoxim showed good efficacy (herbicidal power) when sprayed after being dissolved in acetone, but when a surface active agent was used to form a herbicidal emulsion composite of the substance, as usually prescribed for actual use by farmers, this resulted in severe fluctuations in efficacy or even total ineffectiveness in certain cases, making Pyribenzoxim a very unique case where commercialization was impossible without also developing a separate concoction to commercialize the substance. Up until the plaintiff joined the defendant company, no solution had been found to this problem and research to develop such a concoction remained in a state of confusion. (2) In October 1994, the plaintiff accepted an offer to lead product development for Pyribenzoxim at the defendant company, and joined the company as "Herbicide PL (Project Leader)." The PL position, as opposed to GL (Group Leader) position for a general management, required the ability to involve oneself in the experimental aspects of a specific field and to lead efforts in product development and commercialization of research findings (3) When the non-party 1, who had been in charge of researching development of concoctions, left the company in August 1995, the plaintiff put the non-party 2 in charge of developing the concoction necessary to commercialize Pyribenzoxim. Toward the end of 1995, the plaintiff directly involved himself in registration testing, toxicity testing, mass production procedures and residue testing, etc., necessary at the commercialization stage of Pyribenzoxim. These efforts led to the establishment of a theoretical basis for the amount of surfactant necessary to ensure superb herbicidal effects, and the discovery that one of the reasons behind the substance showing such severe variation in its effect and damage was because fluctuations in deposit amounts had increased due to different spraying conditions, nozzles and mixed use with other chemicals. (4) As a result, in December 1996 the plaintiff's research team completed their invention of a herbicidal emulsion composite that solved the unique problems presented above, listed as the No. 1 patented invention in the ruling of the court below.
Based on the above facts, the court below ruled to the purport that the plaintiff fell under the scope of joint inventor for the No. 1 patented invention for his contributions made as a project leader throughout research for the No. 1 patented invention, conceptualizing concrete steps, tasking subordinates to develop and realize these steps and ultimately making the invention possible when no research breakthroughs had been made before.
The court below established the following facts as well. Upon learning that another herbicide candidate (K11451), manufactured by a research team led by the non-party 3 at Korea Research Institute of Chemical Technology, showed an ability to prevent barnyard millet to an extent that was uniquely superior to other sulphonylurea herbicides, but the commercialization of same had been suspended at the product development stage for seven years due to its irregular effects and high level of toxicity, the plaintiff proposed joint research with the non-party 3 to develop this substance as a herbicide for use within the country. After receiving candidate substances (K11451, K12993, etc.) from the non-party 3, the plaintiff proposed the idea to test whether adding further protective groups to the hydroxyl groups of K11451 and K12993 would alleviate their toxicity, and involved himself in subsequent experiments for which he had also proposed new methods to evaluate the efficacy of substances. Among the resulting substances from modification of K12993, LGC-42153 was chosen to complete the invention of a herbicidal pyridine sulphonylurea (generically referred to as Flucetosulfuron) in 2000, listed as the No. 2 patented invention. Based on these facts, the court below ruled to the purport that the plaintiff fell under the scope of joint inventor for the No. 2 patented invention as well, for his contributions made throughout research for the No. 2 patented invention, conceptualizing concrete steps, tasking subordinates to develop and realize these steps and ultimately making the invention possible at a time when no research breakthroughs had been made before.
In light of the legal principles examined above and the record, we affirm all of the fact-findings and rulings by the court below as being just.
The judgment below commits no such errors in law as claimed in the grounds for appeal, by misapprehending legal principles about determination of a joint inventor or by violating the rules for evidence collection, etc.
2. The defendant's third ground for appeal
A compensation claim for an invention made in connection with employment (an "employee invention") is barred because of the extinctive prescription if not exercised for ten years, just as with general claims. Generally speaking, the starting point of running of an extinctive prescription period is when the employer succeeds from the employee the right to obtain a patent for the invention. However, in cases where a company has internal regulations defining a time period to pay compensation for employee inventions, this prescribed time of payment becomes the starting point of running of the extinctive prescription period, out of consideration that an employee has a legal barrier from exercising her right to claim compensation before this time has come.
According to the reasoning of its judgment, the court below determined that, as the internal regulations regarding an employee invention at the defendant company prescribe compensation for the No. 1 patented invention to take place after the head of the relevant division and company officer in charge of intellectual property had determined that the employee had contributed to the company by inventing No.1 patented invention, with the first installment of this payment to be issued after evaluation of performance throughout the accounting year following release of product, it became possible for the plaintiff to exercise his right to a compensation claim for an employee invention only after performance had been evaluated for the accounting year following February 1997, when Pyribenzoxim had been released as a product. As no evidence had been produced to establish such an evaluation had taken place, the court below then determined the starting point of extinctive period as being after 1998, the next accounting year following release of Pyribenzoxim as a product, thus ruled that the extinctive prescription period for the above compensation claim for employee invention had not been completed at the time of suit for this case, which was filed on Aug. 31, 2007, i.e., within ten years since the prescription period started to run.
Upon examination of the legal principles reviewed above and the record, we affirm this ruling by the court below as being just.
The judgment of the court below contains no such errors in law as claimed in the grounds for appeal, like misapprehending legal principles about the beginning point for the extinctive period.
3. The defendant's fourth ground for appeal and the plaintiff's grounds for appeal
A. Article 40 (2) of the former Patent Act (amended by Act No. 6411 of Feb. 3, 2001) states that, in cases where the employer succeeds to the right to obtain a patent or the patent right for an employee invention, the amount of compensation to be paid to the employee should be determined upon consideration of the amount of profits which the employer makes on the invention and the degree of contribution made by the employer for completion of the invention. Article 39 (1) of the same Act states that, even when the employer has not succeeded to a patentable right for such an employee invention, the employer shall have an ordinary right of use of the invention. Therefore, in this context the amount of profit made by the employer signifies more than profit realized through an ordinary right of use and indicates the amount of profit acquired through the right to exclusive and monopolistic use.
Meanwhile, the amount of profits made by the employer in this context signifies profit gained due to the employee invention itself, not the accounting profit left after balancing profit with cost. As so, if there is profit arising from the employee invention itself there is profit made by the employer, and even when the product manufactured and sold by the employer does not fall under the scope of right for the employee invention, if this product is a substitute that carries the employee invention and the patent right on the employee invention prevents competing companies from using such invention, thus increasing sales for the product, this profit can be assessed as the user's profit made from the employee invention.
B. According to the reasoning of its judgment, the court below assessed the amount of compensation for employee invention in regard to the No. 1 patented invention, to be paid by the defendant company to the plaintiff, as follows. Sales realized by the defendant company when exercising or possessing exclusive rights for the No. 1 patented invention were calculated as one fourth (1/4) of total sales projected for Pyribenzoxim. This figure was reached based on the fact that, even when viewing the 3%, 5% Pyribenzoxim concoction products as not falling under the scope of right for the No. 1 patented invention, they are products that substitute the demand for a product that carries No. 1 patented invention and prevent competing companies from exercising the No. 1 patented invention, thus increasing sales for this product. The assessment was also based on the fact that the No. 1 patented invention has a weak monopolistic nature for overseas markets. Considering that the license fee for patent rights related to the No. 2 patented invention was 3%, the license fee for the No. 1 patented invention was set at 3% as well, which is the general rate used in the industry of agricultural chemicals, in order to calculate the profit realized by the defendant from the No. 1 patented invention. Then, based on the fact that the defendant company had invested 12.8 billion won in R&D costs for Pyribenzoxim up to 2007, that the defendant company was already in possession of two substance patents and six manufacturing process patents related to Pyribenzoxim, and that research had already been in progress, albeit remaining in a state of confusion before the plaintiff had joined the company, the compensation rate for a joint inventor was set at 10% by the court.
Based on the above premise, the court below then determined the amount of compensation for employee invention in regard to the No. 2 patented invention, to be paid by the defendant company to the plaintiff, as follows. Sales realized by the defendant company by exercising the No. 2 patented invention exclusively and monopolistically were calculated as one third (1/3) of total sales projected for Flucetosulferon. Considering that the license fee for patent rights related to the No. 2 patented invention was 3%, the license fee for the No. 2 patented invention was set at 3% as well, the rate generally used in the industry of agricultural chemicals, in order to calculate the profit realized by the defendant due to the No. 1 patented invention. Then, based on the fact that the defendant company had invested 12.7 billion won in R&D costs for Flucetosulferon up to 2007, that this substance was based on a candidate substance already invented at the Korea Research Institute of Chemical Technology, and that the defendant company had already acquired three licenses for the use of related patents and was in possession of two manufacturing process patents related to Flucetosulferon, the compensation rate for a joint inventor was set at 20%.
In light of the legal principles reviewed above and the records, we affirm the facts established at the court below and its rulings as being just.
The judgment of the court below contains no such errors in law as claimed in each of the grounds for appeal, like misapprehending legal principles about assessment of compensation for an employee invention or by violating the rules of evidence.
The Supreme Court precedent cited in the defendant's grounds for appeal is concerned with different issues and thus not suitable for application to this case.
4. Conclusion
Therefore we dismiss all appeals and assess costs of appeal against each of the parties. It is decided as per the Disposition upon the assent of all participating Justices.
Justices Yang Chang-soo (Presiding Justice)
Kim Ji-hyung (Justice in charge)
Jeon Soo-ahn
Lee Sang-hoon
[Main Issues and Holdings]
[1] Criteria to determine whether a person is considered to be a joint inventor
[2] In a case where Gap worked at Eul corporation as Project Leader in charge of product development for Pyribenzoxim and other herbicides, contributed to full-scale commercialization of Pyribenzoxim by directly involving himself in various experiments and, upon learning that commercialization of another herbicide candidates manufactured by Byung's research team in the Korea Research Institute of Chemical Technology had been suspended at the product development stage due to its high level of toxicity, proposed joint research to solve this toxicity issue, eventually allowing Eul corporation to complete its patented invention for a herbicidal emulsion composite and patented invention for a herbicidal pyridine sulphonylurea, the Court affirmed the judgment of the court below to acknowledge Gap as joint inventor for the above inventions
[3] The extinctive period for a compensation claim to an employee invention (=10 years) and the point that the period begins to run
[4] The meaning of "profit realized by the employer," as stipulated in Article 40 (2) of the former Patent Act to consider when assessing compensation amounts for an employee invention
[Summary of Decision]
[1] A joint inventor must be established as being in a relationship of mutual cooperation, on an actual basis, toward completion of the invention. Accordingly, the status of a joint inventor is acknowledged when a person has contributed toward completion of the invention by more than merely providing basic tasks or ideas for the invention, providing general administration for researchers, organizing data and performing experiments upon instruction by a researcher, or supporting or commissioning completion of the invention by providing funds or equipment. Rather, a joint inventor must have contributed toward the invention by newly presenting or adding/supplementing concrete conceptions in regard to technical problems within the invention, materializing new conceptions by conducting experiments, etc., or providing concrete means and methods to achieve the purpose and utility of the invention or by providing actual advice and/or instructions that make the invention possible.
In other words, a person must have contributed toward creational activity of the technical idea to an actual extent in order to be recognized as a joint inventor. Meanwhile, in the case of chemical inventions, which take place in a field frequently referred to as "the science of experiments," notwithstanding certain disparities that may be caused by the contents and technical level of an invention in this field, there are many cases where the invention substantially lacks predictability or implementability and thus cannot be seen as a complete invention without a trial experiment to present experiment data. In such cases, the status of a joint inventor must be decided considering whether the person in question made actual contributions toward specifically defining and completing the invention in the process of experiment.
[2] In a case where Gap worked at Eul corporation as Project Leader (PL) in charge of product development for Pyribenzoxim, a herbicide invented by modifying bispyribac and used for direct-seeded rice, and other herbicides, contributed to full-scale commercialization of Pyribenzoxim by directly involving himself in various experiments for registration testing, toxicity testing, mass production procedures and residue testing, etc., and, upon learning that commercialization of another herbicide candidates manufactured by a research team led by Byung at the Korea Research Institute of Chemical Technology had been suspended at the product development stage due to its high level of toxicity, proposed joint research to solve this toxicity issue, eventually allowing Eul corporation to complete its patented invention for a herbicidal emulsion composite and a patented invention for a herbicidal pyridine sulphonylurea (generic name "Flucetosulfuron"), the Court affirms the judgment of the court below which acknowledged Gap as joint inventor for the above inventions, on the grounds that Gap had made the invention possible by providing concrete conceptions in his capacity as PL, enabling subordinates to proceed with and realize advances during the process of the patented invention, and by providing specific guidance when research remained in a state of confusion.
[3] A compensation claim for an invention made in connection with employment (an "employee invention") is barred because of the extinctive prescription if not exercised for ten years, just as with general claims. Generally speaking, the starting point of running of an extinctive prescription period is when the employer succeeds from the employee the right to obtain a patent for the invention. However, in cases where a company has internal regulations defining a time period to pay compensation for employee inventions, this prescribed time of payment becomes the starting point of running of the extinctive prescription period, out of consideration that an employee has a legal barrier from exercising his/her right to claim compensation before this time has come.
[4] Article 40 (2) of the former Patent Act (amended by Act No. 6411 of Feb. 3, 2001) states that, in cases where the employer succeeds to the right to obtain a patent or the patent right for an employee invention, the amount of compensation to be paid to the employee should be determined upon consideration of the amount of profits which the employer makes on the invention and the degree of contribution made by the employer for completion of the invention. Article 39 (1) of the same Act states that, even when the employer has not succeeded to a patentable right for such an employee invention, the employer shall have an ordinary right of use of the invention. Therefore, in this context the amount of profit made by the employer signifies more than profit realized through an ordinary right of use and indicates the amount of profit acquired through the right to exclusive and monopolistic use.
Meanwhile, the amount of profits made by the employer in this context signifies profit gained due to the employee invention itself, not the accounting profit left after balancing profit with cost. As so, if there is profit arising from the employee invention itself there is profit made by the employer, and even when the product manufactured and sold by the employer does not fall under the scope of right for the employee invention, if this product is a substitute that carries the employee invention and the patent right on the employee invention prevents competing companies from using such invention, thus increasing sales for the product, this profit can be assessed as the user's profit made from the employee invention.
[Reference Provisions] [1] Article 33 (2) of the former Patent Act (amended by Act No. 6411 of Feb. 3, 2001) / [2] Article 33 (2), Article 39 of the former Patent Act (amended by Act No. 6411 of Feb. 3, 2001) (see Article 10 of the current Invention Promotion Act) / [3] Article 39, Article 40 of the former Patent Act (amended by Act No. 6411 of Feb. 3, 2001) (see Article 10, Article 15 of the current Invention Promotion Act), Article 162, Article 166 (1) of the Civil Act / [4] Article 39 (1), Article 40 (1) (2) of the former Patent Act (amended by Act No. 6411 of Feb. 3, 2001) (see Article 10, Article 15 (1), (3) of the current Invention Promotion Act)
Article 33 of the former Patent Act (Person Entitled to Obtain Patent) (2) If two or more persons make jointly an invention, they shall have jointly the patentable right.
Article 39 of the former Patent Act (Employee's Invention) (1) If an invention made by an employee, officer of a corporation or public official (hereinafter referred to as an "employee, etc.") in connection with his duties belongs by its nature to the scope of activities of the employer, corporation, State or local government (hereinafter referred to as an "employer, etc."), and if the employee, etc. or a person who has succeeded to a patentable right, obtains a patent for an invention the inventive act of which belongs to the present or past duties of the employee, etc. (hereinafter referred to as an "employee's invention"), the employer, etc. shall have an ordinary license on such patent right.
(2) Any employee's invention made by a public official shall be succeeded to the State, and the patent right to such employee's invention of a public official, to which the State succeeds, shall be owned by the State.
(3) Except employee's inventions of those made by employee, etc., any clause of a contract or service rules which allows employer, etc. to succeed, in advance, to a right to obtain a patent or a patent right, or which establishes an exclusive license in favor of employer, etc., shall become null and void.
(4) Notwithstanding the provisions of State Properties ActArticle 6 of the State Properties Act, the disposal and management of any patent right owned by the State under paragraph (2) shall be controlled by the Commissioner of the Korean Industrial Property Office.
(5) Matters necessary for the disposal and management of the State-owned patent rights as referred to in paragraph (4) shall be stipulated by the Presidential Decree.
Article 40 of the former Patent Act (Compensation for Employee's Invention) (1) In the event that employee, etc. have employer, etc. succeed to the right to obtain a patent or the patent right for an employee's invention by a contract or service rules, or establish an exclusive license, they shall be entitled to obtain due compensation.
(2) In determining the amount of compensation as referred to in paragraph (1), the amount of profits which the employer, etc. make on the invention and the degree of contribution made by the employer, etc. for a completion of the invention shall be taken into consideration, and if the employee, etc. present a reasonable method of determination, it shall be taken into consideration.
(3) If the State has succeeded to an employee's invention of a public official under Article 39 (2), the State shall pay a due compensation. In this case, matters necessary for payment of the compensation shall be stipulated by the Presidential Decree.
(4) Deleted.
Article 10 of the Invention Promotion Act (Employee Invention) (1) If an employee acquires a patent or completes the registration of a utility model or design (hereinafter referred to as "patent, etc."), or succeeds to the right to acquire a patent, etc., with regard to an employee invention, the employer shall have a non-exclusive license for the patent, utility model right, or design right (hereinafter referred to as "patent right, etc.").
(2) Notwithstanding paragraph (1), the State or a local government shall succeed to a public official's right to an employee invention, and thus a public official's patent right, etc. for an employee invention, to which the State or a local government succeeds, shall be State property or public property: Provided, That an exclusively responsible organization under the latter part of Article 11 (1) of the Technology Transfer and Commercialization Promotion Act (hereinafter referred to as "exclusively responsible organization") shall succeed to rights of a teaching staff, who works at a national or public school under Article 3 of the Higher Education Act (hereinafter referred to as "national or public school"), to an employee invention, and thus patent rights, etc. of a teaching staff of a national or public school to an employee invention, to which the exclusively responsible organization succeeds, shall be owned by the exclusively responsible organization.
(3) A clause of a contract or employment regulations shall be void, if the clause requires an employee to transfer the right to acquire a patent, etc., or a patent right, etc., to the employer in advance in connection with any invention made by the employee, other than employee inventions, or requires an employee to grant the exclusive license for a patent, etc. to the employer.
(4) Notwithstanding Article 8 of the State Property Act, the disposal and management (including waiver of patent rights, etc.) of patent rights, etc. that become State property pursuant to paragraph (2) shall be under the jurisdiction of the Commissioner of the Korean Intellectual Property Office, and matters necessary for the disposal and management thereof shall be prescribed by Presidential Decree.
Article 15 of the Invention Promotion Act (Compensation for Employee Invention) (1) An employee shall have a right to obtain fair compensation when he/she agrees with his/her employer under a contract or employment regulations to have the employer succeed to his/her rights to the patent, etc. for an employee invention or to grant an exclusive license for an employee invention.
(2) In cases where a contract or employment regulations provide for compensation under paragraph (1), the compensation shall be deemed fair, if it is considered reasonable in light of the following conditions:
1. How negotiations were made between the employer and employees when guidelines for determining the form and amount of compensation were established;
2. How the guidelines were presented to employees, such as whether the guidelines established for compensation were publicly announced or posted;
3. How employees' opinions were heard when determining the form and amount of compensation.
(3) If a contract or employment regulations do not provide for compensation under paragraph (1) or if a compensation cannot be considered as fair compensation under paragraph (2), the amount of such compensation shall be determined by taking into consideration benefits the employer is anticipated to obtain with the invention and the degree of contribution of the employer and the employee to the completion of the invention.
(4) The State or a local government shall pay fair compensation, when it succeeds to rights to an employee invention made by a public official pursuant to Article 10 (2). In such cases, matters necessary for the payment of compensation shall be prescribed by Presidential Decree or Municipal Ordinance.
Article 162 of the Civil Act (Extinctive Prescription of Claims or Property Right) (1) The extinctive prescription of a claim shall become complete if not exercised for a period of ten years.
(2) The extinctive prescription of property rights, other than a claim and ownership, shall become complete if not exercised for a period of twenty years.
Article 166 of the Civil Act (Starting Point of Computing Extinctive Prescription) (1) Extinctive prescription shall run from the time it becomes possible to exercise a certain right.
[Reference Cases] [1] Supreme Court Decision 99Hu468 decided Nov. 27, 2001, Supreme Court Decision 2001Hu65 decided Nov. 30, 2001 (Gong2002Sang, 216)
[Plaintiff-Appellee-Appellant] Plaintiff (Law Firm Apex, Attorneys Park Gyun-je et al., Counsel for plaintiff-appellee-appellant)
[Defendant-Appellant-Appellee] LG Life Sciences Ltd. (Law Firm Lee & Ko, Attorneys Lee Gyu-hong et al., Counsel for defendant-appellant-appellee)
[Judgment of the court below] Seoul High Court Decision 2008Na119134 decided Aug. 20, 2009
[Disposition] All appeals are dismissed. Costs of appeals are assessed to each parties.
[Reasoning] The grounds for appeal are examined as follows.
1. The defendant's first and second grounds for appeal
A. A joint inventor must be established as being in a relationship of mutual cooperation, on an actual basis, toward completion of the invention (see Supreme Court Decision 99Hu468, Nov. 27, 2001). Accordingly, the status of a joint inventor can be acknowledged when a person has contributed toward completion of the invention by more than merely providing basic tasks or ideas for the invention, providing general administration for researchers, organizing data and performing experiments upon instruction by a researcher, or supporting or commissioning completion of the invention by providing funds or equipment. Rather, a joint inventor must have contributed toward the invention by newly presenting or adding/supplementing concrete conceptions in regard to technical problems within the invention, materializing such new conceptions by conducting experiments, etc., or providing concrete means and methods to achieve the purpose and effect of the invention or by providing concrete advice or instructions that make the invention possible. In other words, a person must have contributed toward creational activity of the technical idea to an actual extent in order to be recognized as a joint inventor. Meanwhile, in the case of chemical inventions, which take place in a field frequently referred to as "the science of experiments," notwithstanding certain disparities that may be caused by the contents and technical level of an invention in this field, there are many cases where the invention substantially lacks predictability or implementability and thus cannot be seen as a complete invention without a trial experiment to present experiment data. (see Supreme Court Decision 2001Hu65, Nov. 30, 2001). In such cases, the status of a joint inventor must be decided considering whether the person in question made actual contributions toward specifically defining and completing the invention in the process of experiment.
B. According to the reasoning of its judgment, the following facts were established at the court below. (1) Researchers at the defendant company invented the substance Pyribenzoxim in 1991 by modifying bispyribac, a herbicide used for direct-seeded rice. In lab tests Pyribenzoxim showed good efficacy (herbicidal power) when sprayed after being dissolved in acetone, but when a surface active agent was used to form a herbicidal emulsion composite of the substance, as usually prescribed for actual use by farmers, this resulted in severe fluctuations in efficacy or even total ineffectiveness in certain cases, making Pyribenzoxim a very unique case where commercialization was impossible without also developing a separate concoction to commercialize the substance. Up until the plaintiff joined the defendant company, no solution had been found to this problem and research to develop such a concoction remained in a state of confusion. (2) In October 1994, the plaintiff accepted an offer to lead product development for Pyribenzoxim at the defendant company, and joined the company as "Herbicide PL (Project Leader)." The PL position, as opposed to GL (Group Leader) position for a general management, required the ability to involve oneself in the experimental aspects of a specific field and to lead efforts in product development and commercialization of research findings (3) When the non-party 1, who had been in charge of researching development of concoctions, left the company in August 1995, the plaintiff put the non-party 2 in charge of developing the concoction necessary to commercialize Pyribenzoxim. Toward the end of 1995, the plaintiff directly involved himself in registration testing, toxicity testing, mass production procedures and residue testing, etc., necessary at the commercialization stage of Pyribenzoxim. These efforts led to the establishment of a theoretical basis for the amount of surfactant necessary to ensure superb herbicidal effects, and the discovery that one of the reasons behind the substance showing such severe variation in its effect and damage was because fluctuations in deposit amounts had increased due to different spraying conditions, nozzles and mixed use with other chemicals. (4) As a result, in December 1996 the plaintiff's research team completed their invention of a herbicidal emulsion composite that solved the unique problems presented above, listed as the No. 1 patented invention in the ruling of the court below.
Based on the above facts, the court below ruled to the purport that the plaintiff fell under the scope of joint inventor for the No. 1 patented invention for his contributions made as a project leader throughout research for the No. 1 patented invention, conceptualizing concrete steps, tasking subordinates to develop and realize these steps and ultimately making the invention possible when no research breakthroughs had been made before.
The court below established the following facts as well. Upon learning that another herbicide candidate (K11451), manufactured by a research team led by the non-party 3 at Korea Research Institute of Chemical Technology, showed an ability to prevent barnyard millet to an extent that was uniquely superior to other sulphonylurea herbicides, but the commercialization of same had been suspended at the product development stage for seven years due to its irregular effects and high level of toxicity, the plaintiff proposed joint research with the non-party 3 to develop this substance as a herbicide for use within the country. After receiving candidate substances (K11451, K12993, etc.) from the non-party 3, the plaintiff proposed the idea to test whether adding further protective groups to the hydroxyl groups of K11451 and K12993 would alleviate their toxicity, and involved himself in subsequent experiments for which he had also proposed new methods to evaluate the efficacy of substances. Among the resulting substances from modification of K12993, LGC-42153 was chosen to complete the invention of a herbicidal pyridine sulphonylurea (generically referred to as Flucetosulfuron) in 2000, listed as the No. 2 patented invention. Based on these facts, the court below ruled to the purport that the plaintiff fell under the scope of joint inventor for the No. 2 patented invention as well, for his contributions made throughout research for the No. 2 patented invention, conceptualizing concrete steps, tasking subordinates to develop and realize these steps and ultimately making the invention possible at a time when no research breakthroughs had been made before.
In light of the legal principles examined above and the record, we affirm all of the fact-findings and rulings by the court below as being just.
The judgment below commits no such errors in law as claimed in the grounds for appeal, by misapprehending legal principles about determination of a joint inventor or by violating the rules for evidence collection, etc.
2. The defendant's third ground for appeal
A compensation claim for an invention made in connection with employment (an "employee invention") is barred because of the extinctive prescription if not exercised for ten years, just as with general claims. Generally speaking, the starting point of running of an extinctive prescription period is when the employer succeeds from the employee the right to obtain a patent for the invention. However, in cases where a company has internal regulations defining a time period to pay compensation for employee inventions, this prescribed time of payment becomes the starting point of running of the extinctive prescription period, out of consideration that an employee has a legal barrier from exercising her right to claim compensation before this time has come.
According to the reasoning of its judgment, the court below determined that, as the internal regulations regarding an employee invention at the defendant company prescribe compensation for the No. 1 patented invention to take place after the head of the relevant division and company officer in charge of intellectual property had determined that the employee had contributed to the company by inventing No.1 patented invention, with the first installment of this payment to be issued after evaluation of performance throughout the accounting year following release of product, it became possible for the plaintiff to exercise his right to a compensation claim for an employee invention only after performance had been evaluated for the accounting year following February 1997, when Pyribenzoxim had been released as a product. As no evidence had been produced to establish such an evaluation had taken place, the court below then determined the starting point of extinctive period as being after 1998, the next accounting year following release of Pyribenzoxim as a product, thus ruled that the extinctive prescription period for the above compensation claim for employee invention had not been completed at the time of suit for this case, which was filed on Aug. 31, 2007, i.e., within ten years since the prescription period started to run.
Upon examination of the legal principles reviewed above and the record, we affirm this ruling by the court below as being just.
The judgment of the court below contains no such errors in law as claimed in the grounds for appeal, like misapprehending legal principles about the beginning point for the extinctive period.
3. The defendant's fourth ground for appeal and the plaintiff's grounds for appeal
A. Article 40 (2) of the former Patent Act (amended by Act No. 6411 of Feb. 3, 2001) states that, in cases where the employer succeeds to the right to obtain a patent or the patent right for an employee invention, the amount of compensation to be paid to the employee should be determined upon consideration of the amount of profits which the employer makes on the invention and the degree of contribution made by the employer for completion of the invention. Article 39 (1) of the same Act states that, even when the employer has not succeeded to a patentable right for such an employee invention, the employer shall have an ordinary right of use of the invention. Therefore, in this context the amount of profit made by the employer signifies more than profit realized through an ordinary right of use and indicates the amount of profit acquired through the right to exclusive and monopolistic use.
Meanwhile, the amount of profits made by the employer in this context signifies profit gained due to the employee invention itself, not the accounting profit left after balancing profit with cost. As so, if there is profit arising from the employee invention itself there is profit made by the employer, and even when the product manufactured and sold by the employer does not fall under the scope of right for the employee invention, if this product is a substitute that carries the employee invention and the patent right on the employee invention prevents competing companies from using such invention, thus increasing sales for the product, this profit can be assessed as the user's profit made from the employee invention.
B. According to the reasoning of its judgment, the court below assessed the amount of compensation for employee invention in regard to the No. 1 patented invention, to be paid by the defendant company to the plaintiff, as follows. Sales realized by the defendant company when exercising or possessing exclusive rights for the No. 1 patented invention were calculated as one fourth (1/4) of total sales projected for Pyribenzoxim. This figure was reached based on the fact that, even when viewing the 3%, 5% Pyribenzoxim concoction products as not falling under the scope of right for the No. 1 patented invention, they are products that substitute the demand for a product that carries No. 1 patented invention and prevent competing companies from exercising the No. 1 patented invention, thus increasing sales for this product. The assessment was also based on the fact that the No. 1 patented invention has a weak monopolistic nature for overseas markets. Considering that the license fee for patent rights related to the No. 2 patented invention was 3%, the license fee for the No. 1 patented invention was set at 3% as well, which is the general rate used in the industry of agricultural chemicals, in order to calculate the profit realized by the defendant from the No. 1 patented invention. Then, based on the fact that the defendant company had invested 12.8 billion won in R&D costs for Pyribenzoxim up to 2007, that the defendant company was already in possession of two substance patents and six manufacturing process patents related to Pyribenzoxim, and that research had already been in progress, albeit remaining in a state of confusion before the plaintiff had joined the company, the compensation rate for a joint inventor was set at 10% by the court.
Based on the above premise, the court below then determined the amount of compensation for employee invention in regard to the No. 2 patented invention, to be paid by the defendant company to the plaintiff, as follows. Sales realized by the defendant company by exercising the No. 2 patented invention exclusively and monopolistically were calculated as one third (1/3) of total sales projected for Flucetosulferon. Considering that the license fee for patent rights related to the No. 2 patented invention was 3%, the license fee for the No. 2 patented invention was set at 3% as well, the rate generally used in the industry of agricultural chemicals, in order to calculate the profit realized by the defendant due to the No. 1 patented invention. Then, based on the fact that the defendant company had invested 12.7 billion won in R&D costs for Flucetosulferon up to 2007, that this substance was based on a candidate substance already invented at the Korea Research Institute of Chemical Technology, and that the defendant company had already acquired three licenses for the use of related patents and was in possession of two manufacturing process patents related to Flucetosulferon, the compensation rate for a joint inventor was set at 20%.
In light of the legal principles reviewed above and the records, we affirm the facts established at the court below and its rulings as being just.
The judgment of the court below contains no such errors in law as claimed in each of the grounds for appeal, like misapprehending legal principles about assessment of compensation for an employee invention or by violating the rules of evidence.
The Supreme Court precedent cited in the defendant's grounds for appeal is concerned with different issues and thus not suitable for application to this case.
4. Conclusion
Therefore we dismiss all appeals and assess costs of appeal against each of the parties. It is decided as per the Disposition upon the assent of all participating Justices.
Justices Yang Chang-soo (Presiding Justice)
Kim Ji-hyung (Justice in charge)
Jeon Soo-ahn
Lee Sang-hoon